Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET
Company Participants
Anna Marie Wagner - Senior Vice President, Corporate Development
Jason Kelly - Co-Founder & Chief Executive Officer
Mark Dmytruk - Chief Financial Officer
Conference Call Participants
Gaurav Goparaju - Berenberg Bank
Ivy Kozlowski - Goldman Sachs
Anna Marie Wagner
Good afternoon. I'm Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
Thanks as always for joining us. We're looking forward to updating you on our progress. As a reminder, during the presentation today, we'll be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the Securities and Exchange Commission to learn more about these risks and uncertainties.
So, we just hosted our annual conference Ferment and all that's geared towards our customers understanding why customers are choosing Ginkgo is important to our investors. And so we're going to spend some time today recapping some of the themes from that event.
As usual we'll end with a Q&A session and I'll take questions from analysts, investors, and the public. You can submit those questions to us in advance via Twitter #Gingkoresults or e-mail at investors@gingkobioworks.com.
All right. Over to you Jason.
Jason Kelly
Thanks Anna Marie. I'm super excited to be chatting with all of you today. We just hosted Ginkgo Ferment, our big meeting. We had about 1,000 people there in person, plus folks on the live stream as well.
In my keynote, I reminded the audience that at Ginkgo we're not spending our cash just on clinical trials or field trials or cosmetic launches, these are sort of end product activities that our customers are doing.
At Ginkgo, we're spending our capital on improving our platform for our customers. So, a big goal today was learning from our customers about what they want us to build and I firmly believe that if we deliver on those requests then we ultimately deliver for all of our investors. We do right by our customers we do right by all of you. So, you're going to hear a lot more from me today about why customers are choosing to sign up for Ginkgo's platform and what I heard at Ferment.
When we launched Ginkgo one of the big criticisms of our whole model was that a general purpose platform would not work in biotech, right? It might work in the tech industry, but in biology the lab work you do to engineer a mammalian cell is just too different from the lab work you do to engineer bacterial cells to get that working on a common robotics platform and automated for example or the data and machine learning models that would be relevant in the biopharma industry would never port over to work in agriculture.